title: Insulin resistance and polycystic ovary syndrome.
abstract: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in humans, affecting approximately 7-8% of women of reproductive age. Despite the criteria adopted, PCOS is considered to be a predominantly hyperandrogenetic syndrome and the evaluation of metabolic parameters and insulin sensitivity is not mandatory. Most women with PCOS also exhibit features of the metabolic syndrome, including insulin resistance, obesity and dyslipidaemia. While the association with type 2 diabetes is well established, whether the incidence of cardiovascular disease is increased in women with PCOS remains unclear. Acknowledging the strong impact of insulin-resistance in the genesis of PCOS could be helpful not only to make the diagnosis more robust, but also for conferring better cardiovascular risk prevention. Several current studies support a strong recommendation that women with PCOS should undergo comprehensive evaluation for the metabolic syndrome and recognized cardiovascular risk factors, and receive appropriate treatment as needed. Lifestyle modifications remain the first-line therapy for all obese women with PCOS. However, many of these women do not lose weight easily. Insulin-sensitizing drugs are discussed as a promising and unique therapeutic option for the chronic treatment of PCOS.
authors.affiliation: Section of Endocrinology. Dipartimento di Oncologia Sperimentale e Applicazioni Cliniche, Università degli Studi Palermo, 90127 Palermo, Italy. agalluz@unipa.it
authors.forename: Aldo
authors.initials: A
authors.lastname: Galluzzo
authors.forename: Marco Calogero
authors.initials: MC
authors.lastname: Amato
authors.forename: Carla
authors.initials: C
authors.lastname: Giordano
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000517:prevention & control*; D004777:Environment; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015994:Incidence; D007333:Insulin Resistance; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents